Limited predictive value of PD-L1 TPS for pathological response in NSCLC is not attributable to interobserver variability
Open Access
- 26 June 2026
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 218, 109510
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2025
- Artificial Intelligence–Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 StudyJournal of Thoracic Oncology, 2023
- International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant TherapyJournal of Thoracic Oncology, 2023
- PD‐L1 expression in NSCLC: Role of cell blocks and concordance between samplesDiagnostic Cytopathology, 2020
- IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant TherapyJournal of Thoracic Oncology, 2020
- Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant ChemotherapyClinical Lung Cancer, 2020
- Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell CarcinomaJournal of Thoracic Oncology, 2019
- A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability ResearchJournal of Chiropractic Medicine, 2016
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessmentJournal of Cancer Research and Clinical Oncology, 1997